Cigna earnings beat by $0.04, revenue topped estimates
On Wednesday, Jefferies analyst Kaumil Gajrawala adjusted the price target for Tilray (NASDAQ:TLRY) shares, bringing it down to $1.50 from the previous $2.50. The stock, currently trading at $0.46, has experienced significant volatility, falling nearly 30% in the past week alone. Despite the reduction, the firm continues to recommend a Buy rating for the stock. According to InvestingPro data, analyst targets range from $1.00 to $3.00, suggesting potential upside. Gajrawala explained that the company's sales fell short of expectations, attributing this in part to a strategic focus on profitability over immediate revenue growth, which he views as a beneficial approach for the long term.
Tilray's performance in the beer market also did not meet forecasts, which Gajrawala attributed to the company's ongoing efforts to streamline its portfolio and transition its distribution operations. Despite these challenges, InvestingPro data shows the company maintains a healthy current ratio of 2.54, indicating strong ability to meet short-term obligations. He suggests that the current challenges should be considered as incremental steps toward a more significant future narrative for the company.
Gajrawala highlighted several factors that contribute to a positive outlook on Tilray's prospects. These include the company's leading position in the global cannabis market, an improved financial structure, and a strong presence in the US craft beer sector, which provides a stable source of cash flow.
The analyst's commentary underscores confidence in Tilray's long-term strategy, suggesting that the company's current focus on profitability and market leadership will yield beneficial results. Despite the near-term headwinds, the emphasis on a solid balance sheet and cash flow from its beverage business is expected to support Tilray's growth trajectory moving forward.
In other recent news, Tilray Inc . reported its third-quarter 2025 financial results, revealing a significant revenue miss and a larger-than-expected net loss. The company's earnings per share (EPS) were -$0.87, considerably below the forecasted -$0.0433, while revenue reached $185.78 million against an anticipated $213.56 million. A $700 million non-cash impairment contributed to a reported net loss of $793.5 million. Despite the challenges, Tilray's gross profit increased by 5% to $52 million, and its gross margin improved by 200 basis points to 28%. The company revised its fiscal 2025 revenue guidance to a range of $850-900 million. Tilray remains focused on expanding its international medical cannabis markets and enhancing its beverage and wellness portfolios. Additionally, Tilray is exploring innovative strategies, including the use of cryptocurrency payments and AI in greenhouse operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.